Description
Dabigatran Etexilate Mesylate 110 mg capsules are oral anticoagulants classified as direct thrombin inhibitors. They are primarily prescribed for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and for the treatment or prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). They are also used to prevent venous thromboembolism (VTE) following hip or knee replacement surgery.
Mechanism of Action:
- The capsule contains a prodrug (dabigatran etexilate) that is rapidly converted by esterases in the plasma, gut, and liver into active dabigatran.
- Dabigatran acts as a reversible, competitive inhibitor of both free and fibrin-bound thrombin, preventing the conversion of fibrinogen to fibrin and inhibiting thrombin-induced platelet activation.
Uses:
- Preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF).
- Treating and preventing deep vein thrombosis (DVT) and pulmonary embolism (PE).
- Preventing venous thromboembolism (VTE) in patients undergoing hip or knee replacement surgery.
